| Title |
Possible sertraline-induced extrapyramidal adverse effects in an adolescent
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, May 2016
|
| DOI | 10.2147/ndt.s106562 |
| Pubmed ID | |
| Authors |
Lian-fang Wang, Jin-wen Huang, Si-yang Shan, Jia-hong Ding, Jian-bo Lai, Yi Xu, Shao-hua Hu |
| Abstract |
Sertraline has been considered to be a relatively safe selective serotonin reuptake inhibitor for adolescents for a long time. We report herein a case of a 16-year-old Chinese boy with depression who experienced extrapyramidal-like effects, for example, facial spasm, upper limb dystonia, akathisia, and other disturbed behaviors, while being treated with sertraline 200 mg per day. His movement symptoms were significantly alleviated after the discontinuation of sertraline and the administration of scopolamine. This finding indicates that albeit infrequent, sertraline may cause severe extrapyramidal symptoms in adolescent patients, suggesting that clinicians should be alert to the neurological side effects of sertraline in young patients. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 26% |
| Student > Master | 4 | 17% |
| Student > Bachelor | 2 | 9% |
| Student > Doctoral Student | 2 | 9% |
| Other | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 7 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 30% |
| Psychology | 3 | 13% |
| Neuroscience | 2 | 9% |
| Social Sciences | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 2 | 9% |
| Unknown | 7 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 May 2016.
All research outputs
#17,286,379
of 25,374,647 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,901
of 3,132 outputs
Outputs of similar age
#191,109
of 311,864 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#73
of 99 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,864 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 99 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.